Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk
Introduction Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed. Methods Patients t...
Saved in:
Published in | Annals of surgical oncology Vol. 31; no. 5; pp. 3339 - 3349 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.05.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1068-9265 1534-4681 1534-4681 |
DOI | 10.1245/s10434-024-15030-4 |
Cover
Abstract | Introduction
Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed.
Methods
Patients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively.
Results
Among 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation (
p
= 0.21). Most events were symptomatic (
n
= 16, 62%) and were attributable to pulmonary emboli (
n
= 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02–0.72;
p
= 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9–67.0] vs. 55.0 months [CI 27.5–82.5]; hazard ratio 0.98 [CI 0.54-1.81],
p
= 0.98).
Conclusions
A high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis. |
---|---|
AbstractList | Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed.
Patients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively.
Among 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation (p = 0.21). Most events were symptomatic (n = 16, 62%) and were attributable to pulmonary emboli (n = 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02-0.72; p = 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9-67.0] vs. 55.0 months [CI 27.5-82.5]; hazard ratio 0.98 [CI 0.54-1.81], p = 0.98).
A high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis. Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed.INTRODUCTIONVenous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed.Patients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively.METHODSPatients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively.Among 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation (p = 0.21). Most events were symptomatic (n = 16, 62%) and were attributable to pulmonary emboli (n = 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02-0.72; p = 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9-67.0] vs. 55.0 months [CI 27.5-82.5]; hazard ratio 0.98 [CI 0.54-1.81], p = 0.98).RESULTSAmong 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation (p = 0.21). Most events were symptomatic (n = 16, 62%) and were attributable to pulmonary emboli (n = 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02-0.72; p = 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9-67.0] vs. 55.0 months [CI 27.5-82.5]; hazard ratio 0.98 [CI 0.54-1.81], p = 0.98).A high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis.CONCLUSIONSA high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis. Introduction Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed. Methods Patients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively. Results Among 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation ( p = 0.21). Most events were symptomatic ( n = 16, 62%) and were attributable to pulmonary emboli ( n = 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02–0.72; p = 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9–67.0] vs. 55.0 months [CI 27.5–82.5]; hazard ratio 0.98 [CI 0.54-1.81], p = 0.98). Conclusions A high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis. IntroductionVenous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with peritoneal mesothelioma (PeM) remain undescribed.MethodsPatients treated for PeM were retrospectively identified from our institutional database. The frequency of VTE was assessed and logistic regression modeling was employed to assess VTE risk factors. The association between VTE and overall survival was also ascertained. Recommended thromboprophylaxis for patients who underwent surgery at our institution comprised a single preoperative dose of prophylactic anticoagulation, followed by daily dosing for four weeks postoperatively.ResultsAmong 120 PeM patients, 26 (21.7%) experienced VTE, including 19/91 (20.9%) surgical patients, 4/23 (17.4%) patients who received systemic therapy, and 3/6 (50%) patients who underwent observation (p = 0.21). Most events were symptomatic (n = 16, 62%) and were attributable to pulmonary emboli (n = 16, 62%). The 90-day postoperative VTE rate was 4.4% (4/91), including 1 of 60 patients who underwent index surgical intervention at our institution and 3 patients with surgery elsewhere. A low serum albumin concentration was associated with VTE in non-surgical patients (odds ratio 0.12, confidence interval [CI] 0.02–0.72; p = 0.03). No significant difference in overall survival was observed between patients with and without VTE (median 46.0 months [CI 24.9–67.0] vs. 55.0 months [CI 27.5–82.5]; hazard ratio 0.98 [CI 0.54-1.81], p = 0.98).ConclusionsA high risk of VTE was observed in PeM patients, warranting suspicion throughout the disease trajectory. Postoperative VTE rates were within acceptable limits with 4-week thromboprophylaxis. |
Author | Witmer, Hunter D. D. Reddy, Biren Drazer, Michael W. Kindler, Hedy L. Eng, Oliver S. Ong, Cecilia Dhiman, Ankit Churpek, Jane E. Berger, Yaniv Godley, Frederick A. Turaga, Kiran K. Bansal, Varun V. Bregio, Celyn Mitchell, Owen |
Author_xml | – sequence: 1 givenname: Varun V. surname: Bansal fullname: Bansal, Varun V. organization: Division of Surgical Oncology, Yale School of Medicine – sequence: 2 givenname: Owen surname: Mitchell fullname: Mitchell, Owen organization: Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center – sequence: 3 givenname: Celyn surname: Bregio fullname: Bregio, Celyn organization: Pritzker School of Medicine, University of Chicago Medical Center – sequence: 4 givenname: Hunter D. D. surname: Witmer fullname: Witmer, Hunter D. D. organization: Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medical Center – sequence: 5 givenname: Ankit surname: Dhiman fullname: Dhiman, Ankit organization: Department of Surgery, Medical College of Georgia – sequence: 6 givenname: Frederick A. surname: Godley fullname: Godley, Frederick A. organization: Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medical Center – sequence: 7 givenname: Cecilia surname: Ong fullname: Ong, Cecilia organization: Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medical Center – sequence: 8 givenname: Yaniv surname: Berger fullname: Berger, Yaniv organization: Department of Surgery, Sheba Medical Center, Tel Hashomer, Tel Aviv University – sequence: 9 givenname: Biren surname: Reddy fullname: Reddy, Biren organization: Division of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medical Center – sequence: 10 givenname: Jane E. surname: Churpek fullname: Churpek, Jane E. organization: Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin – sequence: 11 givenname: Michael W. surname: Drazer fullname: Drazer, Michael W. organization: Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center – sequence: 12 givenname: Oliver S. surname: Eng fullname: Eng, Oliver S. organization: Division of Surgical Oncology, Department of Surgery, University of California Irvine – sequence: 13 givenname: Hedy L. surname: Kindler fullname: Kindler, Hedy L. organization: Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center – sequence: 14 givenname: Kiran K. surname: Turaga fullname: Turaga, Kiran K. email: kiran.turaga@yale.edu organization: Division of Surgical Oncology, Yale School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38372861$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1LAzEQhoMo1q8_4EEWvHhZnWw-duNNilrBokjrNSTbrEZ3k5psBf-9qa0KHjyEhJnnnczMu4s2nXcGoUMMp7ig7CxioITmUNAcMyCQ0w20g1kKUV7hzfQGXuWi4GyAdmN8AcAlAbaNBqQiZVFxvIPGj8b5Rcwmz8F32pt0Whu7zLrs3gTbpx9Vm41N9P2zaa3v1Hk2dbV_T0n3lKVgNrKzmXHZg42v-2irUW00B-t7D02vLifDUX57d30zvLjNa1KyPheCNlpTLRSdmbIBXBVCaCi1ZkqpUvFaYC2AaKBUKNXUgpEGBK2BpzQXZA-drOrOg39bmNjLzsbatK1yJk0jC1FUrGJp_oQe_0Ff_CK41J0kQEjJCXCaqKM1tdCdmcl5sJ0KH_J7UQkoVkAdfIzBND8IBrl0Q67ckMkN-eWGXFat_ohq26veetcHZdv_pWQljfPlok34bfsf1SeHLZ0h |
CitedBy_id | crossref_primary_10_1245_s10434_024_15155_6 crossref_primary_10_1016_j_soi_2024_100118 |
Cites_doi | 10.1016/j.jtcvs.2019.12.115 10.1016/j.xjon.2021.02.011 10.1016/j.athoracsur.2007.11.064 10.1001/jama.2008.656 10.1160/TH09-12-0856 10.1016/j.ejca.2012.10.021 10.1182/blood-2013-04-460121 10.1245/s10434-019-07414-8 10.1007/s00384-021-04021-6 10.1016/j.jss.2018.09.022 10.1016/j.jtcvs.2009.02.028 10.1016/j.jtcvs.2019.12.082 10.1016/j.jtcvs.2005.10.027 10.1177/1076029614564861 10.1177/107602960401000413 10.1080/02656736.2020.1742389 10.1245/s10434-021-09941-9 10.1182/blood-2013-04-460147 10.1634/theoncologist.2015-0284 10.1016/j.ygyno.2007.05.040 10.1016/j.ejso.2020.07.041 10.1182/blood.2020007338 10.1016/j.ygyno.2015.07.005 10.21037/atm.2017.03.96 10.1200/JCO.2012.42.4358 10.1002/jso.24746 10.1001/jamasurg.2021.0528 10.20524/aog.2018.0305 10.1182/bloodadvances.2019000975 10.1200/JCO.2009.23.9640 10.1097/00000441-200004000-00013 10.1245/s10434-021-09973-1 10.2147/CMAR.S47094 10.1160/TH05-04-0266 10.1111/j.1538-7836.2007.02374.x 10.1053/j.seminoncol.2014.04.009 10.1016/j.jss.2017.08.053 10.1158/2159-8290.CD-21-0331 10.1245/s10434-020-08324-w 10.1016/S0049-3848(20)30389-3 10.1038/bjc.1998.150 10.1056/NEJM200012213432504 10.1200/JCO.1983.1.6.386 10.1182/blood-2017-03-743211 |
ContentType | Journal Article |
Copyright | Society of Surgical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. Society of Surgical Oncology. |
Copyright_xml | – notice: Society of Surgical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. Society of Surgical Oncology. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
DOI | 10.1245/s10434-024-15030-4 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1534-4681 |
EndPage | 3349 |
ExternalDocumentID | 38372861 10_1245_s10434_024_15030_4 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Irving Harris Foundation |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAWUL BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C1A CAG CCPQU COF CS3 CSCUP DDRTE DIK DL5 DNIVK DPUIP E3Z EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GX1 GXS H13 HEOXT HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD OWW P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOQ YFH YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 PUEGO |
ID | FETCH-LOGICAL-c375t-994fbb4b9a4de7f018299b07bb5aaa7a6c91b903b0449aafc953f094c06aa7693 |
IEDL.DBID | 7X7 |
ISSN | 1068-9265 1534-4681 |
IngestDate | Fri Sep 05 13:35:21 EDT 2025 Sat Aug 16 21:25:55 EDT 2025 Thu Apr 03 07:08:40 EDT 2025 Tue Jul 01 00:43:58 EDT 2025 Thu Apr 24 22:51:40 EDT 2025 Fri Feb 21 02:41:06 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Pulmonary embolism Deep vein thrombosis Mesothelioma Mesothelioma, malignant Venous thromboembolism |
Language | English |
License | 2024. Society of Surgical Oncology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c375t-994fbb4b9a4de7f018299b07bb5aaa7a6c91b903b0449aafc953f094c06aa7693 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 38372861 |
PQID | 3033763064 |
PQPubID | 32486 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2928585106 proquest_journals_3033763064 pubmed_primary_38372861 crossref_primary_10_1245_s10434_024_15030_4 crossref_citationtrail_10_1245_s10434_024_15030_4 springer_journals_10_1245_s10434_024_15030_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20240500 2024-05-00 2024-May 20240501 |
PublicationDateYYYYMMDD | 2024-05-01 |
PublicationDate_xml | – month: 5 year: 2024 text: 20240500 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: United States – name: New York |
PublicationTitle | Annals of surgical oncology |
PublicationTitleAbbrev | Ann Surg Oncol |
PublicationTitleAlternate | Ann Surg Oncol |
PublicationYear | 2024 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | Königsbrügge, Posch, Riedl (CR36) 2016; 21 Seng, Liu, Chiu (CR31) 2012; 30 Raghav, Liu, Overman (CR19) 2021; 11 Yan, Deraco, Baratti (CR24) 2009; 27 Hisada, Mackman (CR39) 2017; 130 Mason, Quader, Blackstone (CR41) 2006; 131 Patel, Anraku, Darling (CR8) 2009; 138 Ghaferi, Schwartz, Pawlik (CR22) 2021; 156 Amer (CR43) 2013; 5 Kim, Bhagwandin, Labow (CR7) 2017; 5 Akhtar-Danesh, Ben-Avi, Agzarian, Shargall (CR45) 2021; 6 Cameron (CR12) 2020; 160 Connolly, Phipps, Francis (CR40) 2014; 41 De León, Bravo-Iñiguez, Fox (CR11) 2020; 160 Boussios, Moschetta, Karathanasi (CR38) 2018; 31 Ozkan, Eser, Er (CR14) 2004; 10 Khan, Kelly, Veerapong, Lowy, Baumgartner (CR16) 2019; 26 Lundbech, Krag, Iversen, Hvas (CR28) 2022; 37 Fox, Kahn (CR37) 2005; 94 Timp, Braekkan, Versteeg, Cannegieter (CR2) 2013; 122 Schuitevoerder, Izquierdo, Plana (CR25) 2020; 27 Tuovila, Erkinaro, Takala (CR18) 2020; 37 Baumgartner, McKenzie, Block, Costantini, Lowy (CR17) 2018; 221 Nguyen, Lee, Libby, Verschraegen (CR10) 2008; 85 Koksal, Safak, Ozcan, Agackiran, Erturk, Findik (CR9) 2016; 22 Dhiman, Fenton, Whitridge (CR27) 2021; 28 Rottenstreich, Kalish, Kleinstern, Yaacov, Dux, Nissan (CR33) 2017; 116 Black, Iasonos, Ahmed, Chi, Barakat, Abu-Rustum (CR44) 2007; 107 Pabinger, Thaler, Ay (CR3) 2013; 122 Khorana, Francis, Culakova, Kuderer, Lyman (CR1) 2007; 5 Paredes, Abdel-Misih, Schmidt, Dillhoff, Pawlik, Cloyd (CR21) 2019; 234 Walker, Card, West, Crooks, Grainge (CR6) 2013; 49 CR23 Nalluri, Chu, Keresztes, Zhu, Wu (CR20) 2008; 300 Folsom, Lutsey, Heckbert, Cushman (CR35) 2010; 104 Ustündağ, Can, Benli, Büyükasik, Ozbek (CR15) 2000; 319 Sørensen, Mellemkjaer, Olsen, Baron (CR42) 2000; 343 Anderson, Morgano, Bennett (CR46) 2019; 3 Moik, Ay, Pabinger (CR5) 2020; 191 Hübner, Kusamura, Villeneuve (CR26) 2020; 46 Lanuke, Mack, Temple (CR30) 2009; 52 Antman, Pomfret, Aisner, MacIntyre, Osteen, Greenberger (CR13) 1983; 1 Nakano, Chahinian, Shinjo (CR32) 1998; 77 Dranichnikov, Mahteme, Cashin, Graf (CR29) 2021; 28 Mulder, Horváth-Puhó, van Es (CR4) 2021; 137 Ataseven, du Bois, Reinthaller (CR34) 2015; 138 JM Baumgartner (15030_CR17) 2018; 221 AZ Paredes (15030_CR21) 2019; 234 T Nakano (15030_CR32) 1998; 77 Y Hisada (15030_CR39) 2017; 130 D Nguyen (15030_CR10) 2008; 85 S Boussios (15030_CR38) 2018; 31 AA Khorana (15030_CR1) 2007; 5 SR Nalluri (15030_CR20) 2008; 300 DP Mason (15030_CR41) 2006; 131 P Dranichnikov (15030_CR29) 2021; 28 B Ataseven (15030_CR34) 2015; 138 F Moik (15030_CR5) 2020; 191 I Pabinger (15030_CR3) 2013; 122 S Khan (15030_CR16) 2019; 26 MH Amer (15030_CR43) 2013; 5 D Schuitevoerder (15030_CR25) 2020; 27 A Dhiman (15030_CR27) 2021; 28 KH Antman (15030_CR13) 1983; 1 RB Cameron (15030_CR12) 2020; 160 15030_CR23 TD Yan (15030_CR24) 2009; 27 HT Sørensen (15030_CR42) 2000; 343 K Raghav (15030_CR19) 2021; 11 Y Ustündağ (15030_CR15) 2000; 319 K Lanuke (15030_CR30) 2009; 52 JF Timp (15030_CR2) 2013; 122 FI Mulder (15030_CR4) 2021; 137 M Lundbech (15030_CR28) 2022; 37 AJ Walker (15030_CR6) 2013; 49 LE De León (15030_CR11) 2020; 160 GC Connolly (15030_CR40) 2014; 41 AR Folsom (15030_CR35) 2010; 104 S Seng (15030_CR31) 2012; 30 DR Anderson (15030_CR46) 2019; 3 J Kim (15030_CR7) 2017; 5 M Tuovila (15030_CR18) 2020; 37 EA Fox (15030_CR37) 2005; 94 A Patel (15030_CR8) 2009; 138 M Hübner (15030_CR26) 2020; 46 O Königsbrügge (15030_CR36) 2016; 21 AA Ghaferi (15030_CR22) 2021; 156 A Rottenstreich (15030_CR33) 2017; 116 D Black (15030_CR44) 2007; 107 GG Akhtar-Danesh (15030_CR45) 2021; 6 M Ozkan (15030_CR14) 2004; 10 D Koksal (15030_CR9) 2016; 22 |
References_xml | – volume: 160 start-page: 1064 issue: 4 year: 2020 end-page: 1073 ident: CR11 article-title: Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.12.115 – volume: 6 start-page: 241 year: 2021 end-page: 245 ident: CR45 article-title: Is asymptomatic postoperative venous thromboembolism associated with long-term survival in patients undergoing lung resection for malignancy? publication-title: JTCVS Open doi: 10.1016/j.xjon.2021.02.011 – volume: 85 start-page: 1032 issue: 3 year: 2008 end-page: 1038 ident: CR10 article-title: Rate of thromboembolic events in mesothelioma publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2007.11.064 – volume: 300 start-page: 2277 issue: 19 year: 2008 end-page: 2285 ident: CR20 article-title: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis publication-title: JAMA doi: 10.1001/jama.2008.656 – volume: 104 start-page: 100 issue: 1 year: 2010 end-page: 104 ident: CR35 article-title: Serum albumin and risk of venous thromboembolism publication-title: Thromb Haemost doi: 10.1160/TH09-12-0856 – volume: 49 start-page: 1404 issue: 6 year: 2013 end-page: 1413 ident: CR6 article-title: Incidence of venous thromboembolism in patients with cancer–a cohort study using linked United Kingdom databases publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.10.021 – volume: 122 start-page: 1712 issue: 10 year: 2013 end-page: 1723 ident: CR2 article-title: Epidemiology of cancer-associated venous thrombosis publication-title: Blood doi: 10.1182/blood-2013-04-460121 – volume: 26 start-page: 2276 issue: 7 year: 2019 end-page: 2284 ident: CR16 article-title: Incidence, risk factors, and prevention strategies for venous thromboembolism after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07414-8 – volume: 37 start-page: 17 issue: 1 year: 2022 end-page: 33 ident: CR28 article-title: Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis publication-title: Int J Colorectal Dis doi: 10.1007/s00384-021-04021-6 – volume: 234 start-page: 103 year: 2019 end-page: 109 ident: CR21 article-title: Predictors of readmission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: J Surg Res doi: 10.1016/j.jss.2018.09.022 – volume: 138 start-page: 843 issue: 4 year: 2009 end-page: 848 ident: CR8 article-title: Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2009.02.028 – volume: 160 start-page: 1074 issue: 4 year: 2020 end-page: 1075 ident: CR12 article-title: Commentary: mesothelioma: the guinness world record holder in thromboembolism publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.12.082 – volume: 131 start-page: 711 issue: 3 year: 2006 end-page: 718 ident: CR41 article-title: Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2005.10.027 – volume: 22 start-page: 390 issue: 4 year: 2016 end-page: 394 ident: CR9 article-title: Thromboembolic events in malignant pleural mesothelioma publication-title: Clin Appl Thromb Hemost doi: 10.1177/1076029614564861 – volume: 10 start-page: 393 issue: 4 year: 2004 end-page: 396 ident: CR14 article-title: Antiphospholipid syndrome associated with malignant mesothelioma presenting with superior vena cava thrombosis: a case report publication-title: Clin Appl Thromb Hemost doi: 10.1177/107602960401000413 – volume: 37 start-page: 293 issue: 1 year: 2020 end-page: 300 ident: CR18 article-title: Hyperthermic intraperitoneal chemotherapy enhances blood coagulation perioperatively evaluated by thromboelastography: a pilot study publication-title: Int J Hyperth doi: 10.1080/02656736.2020.1742389 – volume: 28 start-page: 7772 issue: 12 year: 2021 end-page: 7782 ident: CR29 article-title: Coagulopathy and venous thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-09941-9 – volume: 122 start-page: 2011 issue: 12 year: 2013 end-page: 2018 ident: CR3 article-title: Biomarkers for prediction of venous thromboembolism in cancer publication-title: Blood doi: 10.1182/blood-2013-04-460147 – volume: 21 start-page: 252 issue: 2 year: 2016 end-page: 257 ident: CR36 article-title: Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients publication-title: Oncologist doi: 10.1634/theoncologist.2015-0284 – volume: 107 start-page: 66 issue: 1 year: 2007 end-page: 70 ident: CR44 article-title: Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2007.05.040 – ident: CR23 – volume: 46 start-page: 2292 issue: 12 year: 2020 end-page: 2310 ident: CR26 article-title: Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS ) society recommendations–part I: preoperative and intraoperative management publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.041 – volume: 137 start-page: 1959 issue: 14 year: 2021 end-page: 1969 ident: CR4 article-title: Venous thromboembolism in cancer patients: a population-based cohort study publication-title: Blood doi: 10.1182/blood.2020007338 – volume: 138 start-page: 560 issue: 3 year: 2015 end-page: 565 ident: CR34 article-title: Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.07.005 – volume: 5 start-page: 236 issue: 11 year: 2017 ident: CR7 article-title: Malignant peritoneal mesothelioma: a review publication-title: Ann Transl Med doi: 10.21037/atm.2017.03.96 – volume: 30 start-page: 4416 issue: 35 year: 2012 end-page: 4426 ident: CR31 article-title: Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.4358 – volume: 116 start-page: 914 issue: 7 year: 2017 end-page: 920 ident: CR33 article-title: Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: J Surg Oncol doi: 10.1002/jso.24746 – volume: 156 start-page: 577 issue: 6 year: 2021 end-page: 578 ident: CR22 article-title: STROBE reporting guidelines for observational studies publication-title: JAMA Surgery doi: 10.1001/jamasurg.2021.0528 – volume: 31 start-page: 659 issue: 6 year: 2018 end-page: 669 ident: CR38 article-title: Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives publication-title: Ann Gastroenterol doi: 10.20524/aog.2018.0305 – volume: 3 start-page: 3898 issue: 23 year: 2019 end-page: 3944 ident: CR46 article-title: American society of hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients publication-title: Blood Adv doi: 10.1182/bloodadvances.2019000975 – volume: 27 start-page: 6237 issue: 36 year: 2009 end-page: 6242 ident: CR24 article-title: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.9640 – volume: 319 start-page: 265 issue: 4 year: 2000 end-page: 267 ident: CR15 article-title: Internal carotid artery occlusion in a patient with malignant peritoneal mesothelioma: is it a sign of malignancy-related thrombosis? publication-title: Am J Med Sci doi: 10.1097/00000441-200004000-00013 – volume: 28 start-page: 6955 issue: 12 year: 2021 end-page: 6964 ident: CR27 article-title: Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for patients undergoing cytoreductive surgery with or without HIPEC publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-09973-1 – volume: 5 start-page: 165 year: 2013 end-page: 178 ident: CR43 article-title: Cancer-associated thrombosis: clinical presentation and survival publication-title: Cancer Manag Res doi: 10.2147/CMAR.S47094 – volume: 94 start-page: 362 issue: 2 year: 2005 end-page: 365 ident: CR37 article-title: The relationship between inflammation and venous thrombosis. A systematic review of clinical studies publication-title: Thromb Haemost doi: 10.1160/TH05-04-0266 – volume: 5 start-page: 632 issue: 3 year: 2007 end-page: 634 ident: CR1 article-title: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02374.x – volume: 41 start-page: 302 issue: 3 year: 2014 end-page: 310 ident: CR40 article-title: Platelets and cancer-associated thrombosis publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2014.04.009 – volume: 221 start-page: 183 year: 2018 end-page: 189 ident: CR17 article-title: Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery publication-title: J Surg Res doi: 10.1016/j.jss.2017.08.053 – volume: 11 start-page: 2738 issue: 11 year: 2021 end-page: 2747 ident: CR19 article-title: Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0331 – volume: 27 start-page: 1774 issue: 6 year: 2020 end-page: 1779 ident: CR25 article-title: The Chicago consensus on peritoneal surface malignancies: management of peritoneal mesothelioma publication-title: Ann Surg Oncol doi: 10.1245/s10434-020-08324-w – volume: 191 start-page: S3 issue: Suppl 1 year: 2020 end-page: S11 ident: CR5 article-title: Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future publication-title: Thromb Res doi: 10.1016/S0049-3848(20)30389-3 – volume: 77 start-page: 907 issue: 6 year: 1998 end-page: 912 ident: CR32 article-title: Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma publication-title: Br J Cancer doi: 10.1038/bjc.1998.150 – volume: 52 start-page: 18 issue: 1 year: 2009 end-page: 22 ident: CR30 article-title: A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: Can J Surg – volume: 343 start-page: 1846 issue: 25 year: 2000 end-page: 1850 ident: CR42 article-title: Prognosis of cancers associated with venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJM200012213432504 – volume: 1 start-page: 386 issue: 6 year: 1983 end-page: 391 ident: CR13 article-title: Peritoneal mesothelioma: natural history and response to chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.1983.1.6.386 – volume: 130 start-page: 1499 issue: 13 year: 2017 end-page: 1506 ident: CR39 article-title: Cancer-associated pathways and biomarkers of venous thrombosis publication-title: Blood doi: 10.1182/blood-2017-03-743211 – ident: 15030_CR23 – volume: 1 start-page: 386 issue: 6 year: 1983 ident: 15030_CR13 publication-title: J Clin Oncol doi: 10.1200/JCO.1983.1.6.386 – volume: 22 start-page: 390 issue: 4 year: 2016 ident: 15030_CR9 publication-title: Clin Appl Thromb Hemost doi: 10.1177/1076029614564861 – volume: 234 start-page: 103 year: 2019 ident: 15030_CR21 publication-title: J Surg Res doi: 10.1016/j.jss.2018.09.022 – volume: 28 start-page: 7772 issue: 12 year: 2021 ident: 15030_CR29 publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-09941-9 – volume: 77 start-page: 907 issue: 6 year: 1998 ident: 15030_CR32 publication-title: Br J Cancer doi: 10.1038/bjc.1998.150 – volume: 191 start-page: S3 issue: Suppl 1 year: 2020 ident: 15030_CR5 publication-title: Thromb Res doi: 10.1016/S0049-3848(20)30389-3 – volume: 37 start-page: 17 issue: 1 year: 2022 ident: 15030_CR28 publication-title: Int J Colorectal Dis doi: 10.1007/s00384-021-04021-6 – volume: 137 start-page: 1959 issue: 14 year: 2021 ident: 15030_CR4 publication-title: Blood doi: 10.1182/blood.2020007338 – volume: 49 start-page: 1404 issue: 6 year: 2013 ident: 15030_CR6 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.10.021 – volume: 300 start-page: 2277 issue: 19 year: 2008 ident: 15030_CR20 publication-title: JAMA doi: 10.1001/jama.2008.656 – volume: 30 start-page: 4416 issue: 35 year: 2012 ident: 15030_CR31 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.4358 – volume: 85 start-page: 1032 issue: 3 year: 2008 ident: 15030_CR10 publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2007.11.064 – volume: 138 start-page: 843 issue: 4 year: 2009 ident: 15030_CR8 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2009.02.028 – volume: 26 start-page: 2276 issue: 7 year: 2019 ident: 15030_CR16 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07414-8 – volume: 116 start-page: 914 issue: 7 year: 2017 ident: 15030_CR33 publication-title: J Surg Oncol doi: 10.1002/jso.24746 – volume: 160 start-page: 1064 issue: 4 year: 2020 ident: 15030_CR11 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.12.115 – volume: 319 start-page: 265 issue: 4 year: 2000 ident: 15030_CR15 publication-title: Am J Med Sci doi: 10.1097/00000441-200004000-00013 – volume: 52 start-page: 18 issue: 1 year: 2009 ident: 15030_CR30 publication-title: Can J Surg – volume: 221 start-page: 183 year: 2018 ident: 15030_CR17 publication-title: J Surg Res doi: 10.1016/j.jss.2017.08.053 – volume: 104 start-page: 100 issue: 1 year: 2010 ident: 15030_CR35 publication-title: Thromb Haemost doi: 10.1160/TH09-12-0856 – volume: 343 start-page: 1846 issue: 25 year: 2000 ident: 15030_CR42 publication-title: N Engl J Med doi: 10.1056/NEJM200012213432504 – volume: 46 start-page: 2292 issue: 12 year: 2020 ident: 15030_CR26 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.041 – volume: 138 start-page: 560 issue: 3 year: 2015 ident: 15030_CR34 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.07.005 – volume: 21 start-page: 252 issue: 2 year: 2016 ident: 15030_CR36 publication-title: Oncologist doi: 10.1634/theoncologist.2015-0284 – volume: 31 start-page: 659 issue: 6 year: 2018 ident: 15030_CR38 publication-title: Ann Gastroenterol doi: 10.20524/aog.2018.0305 – volume: 5 start-page: 632 issue: 3 year: 2007 ident: 15030_CR1 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02374.x – volume: 28 start-page: 6955 issue: 12 year: 2021 ident: 15030_CR27 publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-09973-1 – volume: 27 start-page: 1774 issue: 6 year: 2020 ident: 15030_CR25 publication-title: Ann Surg Oncol doi: 10.1245/s10434-020-08324-w – volume: 156 start-page: 577 issue: 6 year: 2021 ident: 15030_CR22 publication-title: JAMA Surgery doi: 10.1001/jamasurg.2021.0528 – volume: 5 start-page: 236 issue: 11 year: 2017 ident: 15030_CR7 publication-title: Ann Transl Med doi: 10.21037/atm.2017.03.96 – volume: 5 start-page: 165 year: 2013 ident: 15030_CR43 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S47094 – volume: 107 start-page: 66 issue: 1 year: 2007 ident: 15030_CR44 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2007.05.040 – volume: 27 start-page: 6237 issue: 36 year: 2009 ident: 15030_CR24 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.9640 – volume: 122 start-page: 2011 issue: 12 year: 2013 ident: 15030_CR3 publication-title: Blood doi: 10.1182/blood-2013-04-460147 – volume: 131 start-page: 711 issue: 3 year: 2006 ident: 15030_CR41 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2005.10.027 – volume: 6 start-page: 241 year: 2021 ident: 15030_CR45 publication-title: JTCVS Open doi: 10.1016/j.xjon.2021.02.011 – volume: 122 start-page: 1712 issue: 10 year: 2013 ident: 15030_CR2 publication-title: Blood doi: 10.1182/blood-2013-04-460121 – volume: 10 start-page: 393 issue: 4 year: 2004 ident: 15030_CR14 publication-title: Clin Appl Thromb Hemost doi: 10.1177/107602960401000413 – volume: 130 start-page: 1499 issue: 13 year: 2017 ident: 15030_CR39 publication-title: Blood doi: 10.1182/blood-2017-03-743211 – volume: 11 start-page: 2738 issue: 11 year: 2021 ident: 15030_CR19 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0331 – volume: 160 start-page: 1074 issue: 4 year: 2020 ident: 15030_CR12 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.12.082 – volume: 3 start-page: 3898 issue: 23 year: 2019 ident: 15030_CR46 publication-title: Blood Adv doi: 10.1182/bloodadvances.2019000975 – volume: 37 start-page: 293 issue: 1 year: 2020 ident: 15030_CR18 publication-title: Int J Hyperth doi: 10.1080/02656736.2020.1742389 – volume: 94 start-page: 362 issue: 2 year: 2005 ident: 15030_CR37 publication-title: Thromb Haemost doi: 10.1160/TH05-04-0266 – volume: 41 start-page: 302 issue: 3 year: 2014 ident: 15030_CR40 publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2014.04.009 |
SSID | ssj0017305 |
Score | 2.4447417 |
Snippet | Introduction
Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural... Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and... IntroductionVenous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3339 |
SubjectTerms | Anticoagulants - therapeutic use Dosage Humans Malignancy Medicine Medicine & Public Health Mesothelioma Mesothelioma - complications Mesothelioma, Malignant Oncology Peritoneal Surface Malignancy Peritoneum Postoperative Complications - etiology Postoperative Complications - prevention & control Pulmonary Embolism - etiology Retrospective Studies Risk Factors Surgery Surgical Oncology Survival Thromboembolism Venous Thromboembolism - etiology Venous Thromboembolism - prevention & control |
SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LahRBsNAExItojGZMlBa8JQ29_ZzOLYSERVgRyYbcmup54OLurGTW_7e6d2ZFooKHmcP0k3p0VU09GuCDbErnKqy41s7RS0mOpfO8dlp7WSKq_Ct79slO5_rjnbkbksL6Mdp9dEnmkzpXQNAmJbtppTnJFE5KjBJcP4Z9k-pJERXP5cXOd0A0a7KP0xIrS2uGVJk_z_G7OHqgYz7wj2axc_0cng36IrvYIvgFPGq6A3gyGzziL2F2m4usspuv9-tVXDf0LBf9ii069pmIK5XapuGzpk-ZVsvFeoXnbN5VKXCT1mP0kU1TFZGOfVn03w5hfn11cznlwxUJvFLObLj3uo1RR4-6blwryFrwPgoXo0FEh7byk-iFioJAj9hW3qiWLLpKWGq2Xr2CvY52cgSM5omI0dZl3RJXGy9R6br0QqCsjS0LmIyQCtVQPzxdY7EMyY4g6IYtdANBN2ToBl3A6W7M9231jH_2PhkREAZO6gOJ2HQGkuZUwPtdM_FAcmxg1xCIgySqSu5NYQt4vUXcbrlkgcvSTgo4GzH5a_K_7-XN_3U_hqcyUVWOhDyBvc39j-YtaSub-C4T509xKt1Z priority: 102 providerName: Springer Nature |
Title | Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk |
URI | https://link.springer.com/article/10.1245/s10434-024-15030-4 https://www.ncbi.nlm.nih.gov/pubmed/38372861 https://www.proquest.com/docview/3033763064 https://www.proquest.com/docview/2928585106 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1rixMxcNA7EL-Ib1fPI4LfNJjNc-MXaaW1KC3HcZX6KST7wGK7PW_r_3eyTXvI4X3YDWw2D-aRmckkMwBveV0YU_qSSmkMvgSnvjCWVkZKywvvRb-VPZ3pyVx-XahF2nDr0rHK_ZrYL9TVpox75B9wqY28gBL00-VvGrNGRe9qSqFxF45z1ERi6gazOBhcOVKv6r2dGpmaa5UuzXCp4tU5KSRFCUVRJRKMyn8F0w1t84antBdA44fwIGmOZLBD9SO4U7eP4d40-cafwPR7H26VXPy82qzDpsZntezWZNmSMySzGHQbm0_rLt65Wi03a_-RzNsyHuHE8Qh-JJMYT6Ql58vu11OYj0cXnyc0JUugpTBqS62VTQgyWC-r2jQM7QZrAzMhKO-98bq0ebBMBIZI8L4prRIN2nYl01itrXgGRy3O5AUQ7Cd4H3RVVA3yt7LcC1kVljHPK6WLDPI9pFyZIonHhBYrFy0KhK7bQdchdF0PXSczeHdoc7mLo3Hr3yd7BLjEU527poAM3hyqkRuii8O3NYLYcaSv6OhkOoPnO8Qdhou2OC90nsH7PSavO___XF7ePpdXcJ9HKurPQJ7A0fbqT_0a9ZRtOO2J8RSOB-PhcBbLLz--jbAcjmZn51g754O_f2Ll-A |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFRtJeBSlXfaAkaCE1hkHT9ipArxaLWlzaqqdlFvxnYSddXdbGkWIX6Ob2OcTbZCFb31kBzi-KHxvDzjmQF4xYpUKW895VwpfCWM2lRpmivONUutTRpTdjaUgzH_eipO1-BPFwsTrlV2PLFh1PncBxv5O2S1gRZQgn64-EFD1ajgXe1KaNi2tEK-26QYawM7Dovfv_AIV-8efMH9fs3Y_t7o84C2VQaoT5RYUK156Rx32vK8UGWMCrfWLlbOCWutstLrvtNx4mJcvbWl1yIp8VDkY4nNMiRjQhGwzoMBpQfrn_aGxycrPwbSj2j8rRLZCpOiDdthXITgPZ5wijKSolKWxJT_Kxqv6bvXfLWNCNzfhI1WdyUfl8h2H9aK6gHcyVrv_EPIvjUJX8no7HI-c_MCn-mknpFJRY4R0UPab-yeFXWI-ppO5jP7nowrHy6R4nwEP5JByGhSkZNJff4IxrcCyMfQq3AlT4HgOM5aJ_M0L5HDCM1swvNUx7FluZBpBP0OUsa3ucxDSY2pCWcahK5ZQtcgdE0DXcMjeLPqc7HM5HHj3zvdBpiWqmtzhYMRvFw1Iz0GJ4utCgSxYYjhwdUaywieLDduNV2wBrBU9iN42-3k1eD_X8vWzWt5AXcHo-zIHB0MD7fhHgsY1dzI3IHe4vJn8Qy1poV73qImge-3TQ1_Aea8JII |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw8DRt0sQL4pvAACPBE1hLHX_ESBMCtqpjtKqmFe3Ns51EVLTpWIoQf5FfxTl1OqGJve0heYjj2Dnfp893B_CKlblS3nrKuVJ4yxi1udK0UJxrllubtVvZw5EcTPjnU3G6AX-6WJhwrLLjiS2jLhY-7JHvIqsNtIASdLeKxyLG-_335z9oqCAVPK1dOQ0byywUe226sRjkcVT-_oXmXLN3uI9r_5qx_sHJpwGNFQeoz5RYUq155Rx32vKiVFWKyrfWLlXOCWutstLrntNp5lL8E2srr0VWoYHkU4nNMiRmQnGwpVDqoyG49fFgND5e-zSQlkTre5XIYpgUMYSHcREC-XjGKcpLigpallL-r5i8ovte8du24rB_B25HPZZ8WCHeXdgo63uwPYye-vsw_NomfyUn3y4Wc7co8ZpNmzmZ1mSMSB9SgGP3YdmECLDZdDG378ik9uFAKY5H8CEZhOwmNTmeNt8fwORGAPkQNmucyWMg-B1nrZNFXlTIbYRmNuNFrtPUskLIPIFeBynjY17zUF5jZoJ9g9A1K-gahK5poWt4Am_Wfc5XWT2ufXunWwATKbwxl_iYwMt1M9JmcLjYukQQG4bYHtyuqUzg0Wrh1sOFnQGWy14Cb7uVvPz4_-fy5Pq5vIBtpArz5XB09BRusYBQ7eHMHdhcXvwsn6ECtXTPI2YSOLtpYvgL0uAoxg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Venous+Thromboembolism+in+Peritoneal+Mesothelioma%3A+Uncovering+the+Hidden+Risk&rft.jtitle=Annals+of+surgical+oncology&rft.au=Bansal%2C+Varun+V&rft.au=Mitchell%2C+Owen&rft.au=Bregio%2C+Celyn&rft.au=Witmer%2C+Hunter+D+D&rft.date=2024-05-01&rft.eissn=1534-4681&rft.volume=31&rft.issue=5&rft.spage=3339&rft_id=info:doi/10.1245%2Fs10434-024-15030-4&rft_id=info%3Apmid%2F38372861&rft.externalDocID=38372861 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon |